Sidley is pleased to present its annual year-in-review addressing developments in securities class actions brought against life sciences companies in 2020.
In this publication, we provide an overview and analysis of trends in decisions involving life sciences companies with products at two distinct stages of development—pre- and post-FDA approval. We also summarize each of the reported federal decisions in this area and catalog the new securities class action complaints filed against life sciences companies in 2020. See more here.